Stock Screener App

무료 -

4.62

3.14% -0.15

Capricor Therapeutics Inc (CAPR)

개요 뉴스 가격 이력 옵션 체인 Financials CAPR 왜 하락? 토론 예측 주식 분할

Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스

A look into Capricor Therapeutics Inc (CAPR)'s deeper side – Sete News - SETE News

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Capricor's cell therapy shows three year benefit in DMD patients - Clinical Trials Arena

Clinical Trials Arena

Capricor's cell therapy shows three year benefit in DMD patients - Yahoo Finance

What's Going On With Capricor Therapeutics Stock Friday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga

Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study - MarketWatch

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - GlobeNewswire

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - WICZ

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - Yahoo Finance

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength? - Yahoo Movies UK

Yahoo Movies UK

Slated Capricor, FDA meeting to focus on DMD therapy deramiocel - Muscular Dystrophy News

Muscular Dystrophy News

Slated Capricor, FDA meeting to focus on DMD therapy deramiocel - Muscular Dystrophy News

Muscular Dystrophy News

FDA sets meeting for Capricor's DMD treatment application By Investing.com - Investing.com

FDA sets meeting for Capricor's DMD treatment application By Investing.com - Investing.com UK

Investing.com UK

CORRECTION: Capricor Therapeutics - ForexTV.com

CORRECTION: Capricor Therapeutics - GlobeNewswire

CORRECTION: Capricor Therapeutics

GlobeNewswire Inc.

Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy - Seeking Alpha

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy - GlobeNewswire

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire Inc.

While shareholders of Capricor Therapeutics (NASDAQ:CAPR) are in the black over 5 years, those who bought a week ago aren't so fortunate - Simply Wall St

Ratios Uncovered: Breaking Down Capricor Therapeutics Inc (CAPR)'s Trailing Twelve Months Metrics – DWinneX - The Dwinnex

Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest - Defense World

Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest - MarketBeat

Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going (CAPR) - Seeking Alpha

(CAPR) Technical Pivots with Risk Controls - Stock Traders Daily

Stock Traders Daily

Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going (CAPR) - Seeking Alpha

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength? - Yahoo Movies UK

Yahoo Movies UK

Pfizer Phase III DMD Gene Therapy Study Misses Goal - Markets Insider

Markets Insider

The Significance of Moving Averages in Capricor Therapeutics Inc Inc. (CAPR) Price Performance - The InvestChronicle

The InvestChronicle

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

Zacks Investment Research

Pfizer's Duchenne gene therapy fails in late-stage study - Yahoo News Canada

Yahoo News Canada

Capricor unit enters into amendment to CIRM notice of loan award - Reuters

Potash America (OTCMKTS:PTAM) Stock Price Crosses Above 50 Day Moving Average of $0.00 - Defense World

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.70 - Defense World

Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.70 - MarketBeat

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.70 - Defense World

Capricor moves forward with FDA on Duchenne treatment By Investing.com - Investing.com

12 Health Care Stocks Moving In Tuesday's After-Market Session - Autonomix Medical (NASDAQ:AMIX), Adlai N - Benzinga

What's Going On With Capricor Therapeutics Stock Tuesday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular ... - GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular ... - Yahoo Finance

What's Going On With Capricor Therapeutics Stock Tuesday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga

Capricor Advances in DMD Therapy With Positive Study Data - Markets Insider

Markets Insider

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data

Zacks Investment Research

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data - Zacks Investment Research

Zacks Investment Research

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data - Yahoo Finance

In DMD, three years of CAP-1002 still showing stabilized arm... - Muscular Dystrophy News

Muscular Dystrophy News

In DMD, three years of CAP-1002 still showing stabilized arm... - Muscular Dystrophy News

Muscular Dystrophy News

Its Stock Has Paid Off Big Time For Capricor Therapeutics Inc – Sete News - SETE News

$81.88

0.55%

$24.85

1.07%

$145.93

2.32%

$78.81

1.99%

$433.34

0.79%

$244.50

0.69%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | Open in MarketWatch | Open in EDGAR | Open in Reuters